Allelic Loss of a Common Microsatellite Marker MYCL1: A Useful Prognostic Factor of Poor Outcomes in Colorectal Cancer

Takeshi Kambara, Gerald B. Sharp, Takeshi Nagasaka, Masanori Takeda, Hiromi Sasamoto, Hitoshi Nakagawa, Hiroshi Isozaki, Donald G. MacPhee, Jeremy R. Jass, Noriaki Tanaka, Nagahide Matsubara

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Purpose: Allelic loss involving chromosome arms 5q, 8p, 17p, and 18q is commonly detected in colorectal cancer (CRC). The short arm of chromosome 1 is also frequently affected in a whole range of cancer types, including CRC. Our aim in the present study was to determine whether allelic losses on lp were likely to be of much value in predicting the prognosis of CRC cases. Experimental Design: Genomic DNA was prepared from tumor and corresponding normal tissue specimens from 90 patients who had undergone curative resection for CRC. Loss of heterozygosity (LOH) on chromosome arms 1p, 2p, 5q, 7q, 8p, 17p, 17q, and 18q was examined using 14 microsatellite markers, and possible correlations between LOH and clinicopathological factors (including tumor recurrence and patient survival) were investigated. LOH at the MYCL1 microsatellite marker at 1p34 was detected in 12 of 74 (16.2%) patients who were informative for this marker. Results: After controlling for tumor stage and gender and excluding findings for patients with remote metastasis, we found that patients who were positive for LOH at MYCL1 were 31 times more likely to experience recurrence than those who were negative for LOH at this locus (95% confidence intervals, 2.27-∞; P = 0.04). There were indications of a similar tendency for LOH at the 14-3-3-σ-TG microsatellite marker at 1p35, but we could find no evidence of a significant association between LOH at this site and tumor recurrence or patient survival. We were also unable to detect significant association between LOH at the various sites on 2p, 5q, 7q, 8p, 17p, 17q, and 18q and either tumor recurrence or patient survival. Conclusions: CRC patients whose tumors exhibited LOH at MYCL1 at chromosome 1p34 were likely to have a poor prognosis, suggesting that this marker may have clinical relevance.

Original languageEnglish
Pages (from-to)1758-1763
Number of pages6
JournalClinical Cancer Research
Volume10
Issue number5
DOIs
Publication statusPublished - Mar 1 2004

Fingerprint

Loss of Heterozygosity
Microsatellite Repeats
Colorectal Neoplasms
Neoplasms
Recurrence
Chromosomes
Survival
Chromosomes, Human, Pair 1
Research Design
Confidence Intervals
Neoplasm Metastasis

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Kambara, T., Sharp, G. B., Nagasaka, T., Takeda, M., Sasamoto, H., Nakagawa, H., ... Matsubara, N. (2004). Allelic Loss of a Common Microsatellite Marker MYCL1: A Useful Prognostic Factor of Poor Outcomes in Colorectal Cancer. Clinical Cancer Research, 10(5), 1758-1763. https://doi.org/10.1158/1078-0432.CCR-0779-3

Allelic Loss of a Common Microsatellite Marker MYCL1 : A Useful Prognostic Factor of Poor Outcomes in Colorectal Cancer. / Kambara, Takeshi; Sharp, Gerald B.; Nagasaka, Takeshi; Takeda, Masanori; Sasamoto, Hiromi; Nakagawa, Hitoshi; Isozaki, Hiroshi; MacPhee, Donald G.; Jass, Jeremy R.; Tanaka, Noriaki; Matsubara, Nagahide.

In: Clinical Cancer Research, Vol. 10, No. 5, 01.03.2004, p. 1758-1763.

Research output: Contribution to journalArticle

Kambara, T, Sharp, GB, Nagasaka, T, Takeda, M, Sasamoto, H, Nakagawa, H, Isozaki, H, MacPhee, DG, Jass, JR, Tanaka, N & Matsubara, N 2004, 'Allelic Loss of a Common Microsatellite Marker MYCL1: A Useful Prognostic Factor of Poor Outcomes in Colorectal Cancer', Clinical Cancer Research, vol. 10, no. 5, pp. 1758-1763. https://doi.org/10.1158/1078-0432.CCR-0779-3
Kambara, Takeshi ; Sharp, Gerald B. ; Nagasaka, Takeshi ; Takeda, Masanori ; Sasamoto, Hiromi ; Nakagawa, Hitoshi ; Isozaki, Hiroshi ; MacPhee, Donald G. ; Jass, Jeremy R. ; Tanaka, Noriaki ; Matsubara, Nagahide. / Allelic Loss of a Common Microsatellite Marker MYCL1 : A Useful Prognostic Factor of Poor Outcomes in Colorectal Cancer. In: Clinical Cancer Research. 2004 ; Vol. 10, No. 5. pp. 1758-1763.
@article{faaadd1f4a7c4db293bec175e3f2d1b6,
title = "Allelic Loss of a Common Microsatellite Marker MYCL1: A Useful Prognostic Factor of Poor Outcomes in Colorectal Cancer",
abstract = "Purpose: Allelic loss involving chromosome arms 5q, 8p, 17p, and 18q is commonly detected in colorectal cancer (CRC). The short arm of chromosome 1 is also frequently affected in a whole range of cancer types, including CRC. Our aim in the present study was to determine whether allelic losses on lp were likely to be of much value in predicting the prognosis of CRC cases. Experimental Design: Genomic DNA was prepared from tumor and corresponding normal tissue specimens from 90 patients who had undergone curative resection for CRC. Loss of heterozygosity (LOH) on chromosome arms 1p, 2p, 5q, 7q, 8p, 17p, 17q, and 18q was examined using 14 microsatellite markers, and possible correlations between LOH and clinicopathological factors (including tumor recurrence and patient survival) were investigated. LOH at the MYCL1 microsatellite marker at 1p34 was detected in 12 of 74 (16.2{\%}) patients who were informative for this marker. Results: After controlling for tumor stage and gender and excluding findings for patients with remote metastasis, we found that patients who were positive for LOH at MYCL1 were 31 times more likely to experience recurrence than those who were negative for LOH at this locus (95{\%} confidence intervals, 2.27-∞; P = 0.04). There were indications of a similar tendency for LOH at the 14-3-3-σ-TG microsatellite marker at 1p35, but we could find no evidence of a significant association between LOH at this site and tumor recurrence or patient survival. We were also unable to detect significant association between LOH at the various sites on 2p, 5q, 7q, 8p, 17p, 17q, and 18q and either tumor recurrence or patient survival. Conclusions: CRC patients whose tumors exhibited LOH at MYCL1 at chromosome 1p34 were likely to have a poor prognosis, suggesting that this marker may have clinical relevance.",
author = "Takeshi Kambara and Sharp, {Gerald B.} and Takeshi Nagasaka and Masanori Takeda and Hiromi Sasamoto and Hitoshi Nakagawa and Hiroshi Isozaki and MacPhee, {Donald G.} and Jass, {Jeremy R.} and Noriaki Tanaka and Nagahide Matsubara",
year = "2004",
month = "3",
day = "1",
doi = "10.1158/1078-0432.CCR-0779-3",
language = "English",
volume = "10",
pages = "1758--1763",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research Inc.",
number = "5",

}

TY - JOUR

T1 - Allelic Loss of a Common Microsatellite Marker MYCL1

T2 - A Useful Prognostic Factor of Poor Outcomes in Colorectal Cancer

AU - Kambara, Takeshi

AU - Sharp, Gerald B.

AU - Nagasaka, Takeshi

AU - Takeda, Masanori

AU - Sasamoto, Hiromi

AU - Nakagawa, Hitoshi

AU - Isozaki, Hiroshi

AU - MacPhee, Donald G.

AU - Jass, Jeremy R.

AU - Tanaka, Noriaki

AU - Matsubara, Nagahide

PY - 2004/3/1

Y1 - 2004/3/1

N2 - Purpose: Allelic loss involving chromosome arms 5q, 8p, 17p, and 18q is commonly detected in colorectal cancer (CRC). The short arm of chromosome 1 is also frequently affected in a whole range of cancer types, including CRC. Our aim in the present study was to determine whether allelic losses on lp were likely to be of much value in predicting the prognosis of CRC cases. Experimental Design: Genomic DNA was prepared from tumor and corresponding normal tissue specimens from 90 patients who had undergone curative resection for CRC. Loss of heterozygosity (LOH) on chromosome arms 1p, 2p, 5q, 7q, 8p, 17p, 17q, and 18q was examined using 14 microsatellite markers, and possible correlations between LOH and clinicopathological factors (including tumor recurrence and patient survival) were investigated. LOH at the MYCL1 microsatellite marker at 1p34 was detected in 12 of 74 (16.2%) patients who were informative for this marker. Results: After controlling for tumor stage and gender and excluding findings for patients with remote metastasis, we found that patients who were positive for LOH at MYCL1 were 31 times more likely to experience recurrence than those who were negative for LOH at this locus (95% confidence intervals, 2.27-∞; P = 0.04). There were indications of a similar tendency for LOH at the 14-3-3-σ-TG microsatellite marker at 1p35, but we could find no evidence of a significant association between LOH at this site and tumor recurrence or patient survival. We were also unable to detect significant association between LOH at the various sites on 2p, 5q, 7q, 8p, 17p, 17q, and 18q and either tumor recurrence or patient survival. Conclusions: CRC patients whose tumors exhibited LOH at MYCL1 at chromosome 1p34 were likely to have a poor prognosis, suggesting that this marker may have clinical relevance.

AB - Purpose: Allelic loss involving chromosome arms 5q, 8p, 17p, and 18q is commonly detected in colorectal cancer (CRC). The short arm of chromosome 1 is also frequently affected in a whole range of cancer types, including CRC. Our aim in the present study was to determine whether allelic losses on lp were likely to be of much value in predicting the prognosis of CRC cases. Experimental Design: Genomic DNA was prepared from tumor and corresponding normal tissue specimens from 90 patients who had undergone curative resection for CRC. Loss of heterozygosity (LOH) on chromosome arms 1p, 2p, 5q, 7q, 8p, 17p, 17q, and 18q was examined using 14 microsatellite markers, and possible correlations between LOH and clinicopathological factors (including tumor recurrence and patient survival) were investigated. LOH at the MYCL1 microsatellite marker at 1p34 was detected in 12 of 74 (16.2%) patients who were informative for this marker. Results: After controlling for tumor stage and gender and excluding findings for patients with remote metastasis, we found that patients who were positive for LOH at MYCL1 were 31 times more likely to experience recurrence than those who were negative for LOH at this locus (95% confidence intervals, 2.27-∞; P = 0.04). There were indications of a similar tendency for LOH at the 14-3-3-σ-TG microsatellite marker at 1p35, but we could find no evidence of a significant association between LOH at this site and tumor recurrence or patient survival. We were also unable to detect significant association between LOH at the various sites on 2p, 5q, 7q, 8p, 17p, 17q, and 18q and either tumor recurrence or patient survival. Conclusions: CRC patients whose tumors exhibited LOH at MYCL1 at chromosome 1p34 were likely to have a poor prognosis, suggesting that this marker may have clinical relevance.

UR - http://www.scopus.com/inward/record.url?scp=12144291455&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=12144291455&partnerID=8YFLogxK

U2 - 10.1158/1078-0432.CCR-0779-3

DO - 10.1158/1078-0432.CCR-0779-3

M3 - Article

C2 - 15014029

AN - SCOPUS:12144291455

VL - 10

SP - 1758

EP - 1763

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 5

ER -